Ruxolitinib therapy for myelofibrosis in Austria: Consensus on therapy management

The oral Janus associated kinase (JAK1/2) inhibitor ruxolitinib has been available for treatment of patients with intermediate or high-risk myelofibrosis in Europe since 2012. Since its introduction, the expertise of prescribing doctors with respect to ruxolitinib function, efficacy and adverse effe...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Wien Klin Wochenschr
Auteurs principaux: Krauth, Maria-Theresa, Burgstaller, Sonja, Buxhofer-Ausch, Veronika, Gastl, Günther, Geissler, Klaus, Keil, Felix, Krippl, Peter, Melchardt, Thomas, Petzer, Andreas, Rumpold, Holger, Sliwa, Thamer, Wöhrer, Stefan, Wölfler, Albert, Gisslinger, Heinz
Format: Artigo
Langue:Inglês
Publié: Springer Vienna 2018
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6132876/
https://ncbi.nlm.nih.gov/pubmed/30043249
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00508-018-1365-5
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires